Blinatumomab and POMP for Acute Lymphoblastic Leukemia

A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)

  • Clinical Trial Information

    Trial Contact: Walton, Sherri

    Trial Phone: 321.841.1907

  • IRB No: SWOG S1318

    Protocol Abbrev: SWOG S1318

    Principal Investigator: Jose E. Sarriera, MD

    Phase: Drug: Phase II

    Age Group: Adult

    Secondary Protocol No: S1318

    Treatment: 6-Mercaptopurine, Methotrexate, Prednisone, Vincristine, Blinatumomab, Dasatinib, Dexamethasone

    Therapies Involved: Chemotherapy ID: NCT02143414

  • Objective

    This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia.

  • Key Eligibility

    •  65 Years and older
    •  Patients must have a new morphologic diagnosis of precursor B cell acute lymphoblastic leukemia (ALL) Patients must have a diagnosis of Philadelphia chromosome negative ALL or Ph chromosome positive ALL non T cell)
    •  Patients must not have received any prior chemotherapy, radiation therapy, or other therapy for the treatment of ALL